{Reference Type}: Journal Article
{Title}: A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia.
{Author}: Kantarjian HM;Jabbour EJ;Lipton JH;Castagnetti F;Brümmendorf TH;
{Journal}: Clin Lymphoma Myeloma Leuk
{Volume}: 24
{Issue}: 5
{Year}: 2024 May 12
{Factor}: 2.822
{DOI}: 10.1016/j.clml.2024.01.005
{Abstract}: The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML. This review details the efficacy of bosutinib for the treatment of CML in the first- and second-line settings, as well as in third- and later-line settings for high-risk patients resistant or intolerant to at least 2 TKIs. It also outlines bosutinib studies that provide evidence for dose-optimization strategies that can be used to improve efficacy and effectively manage adverse events. The studies that provide evidence for specific patient populations benefiting particularly from bosutinib dose-optimization strategies are also discussed. The well-established, long-term side-effect profile and the potential to make dose adjustments with bosutinib make it an appropriate treatment option for patients with CML. Bosutinib has demonstrated a positive impact on health-related quality of life and an important role in the long-term treatment of patients with CML.